OncLive TV

John Zalcberg, ​PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

John Zalcberg, ​PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor​.

Michael J. Cavnar, MD, discusses the importance of multidisciplinary care in colorectal cancer.

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Weijing Sun, MD, FACP, discusses the ​use of ramucirumab plus paclitaxel in metastatic gastric cancer.

Michael J. Cavnar, MD, discusses the management of patients with liver metastas​es in colorectal cancer.

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.